Analysis of U.S. Patent 6,878,749: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,878,749?
U.S. Patent 6,878,749, granted on April 12, 2005, primarily covers a method of treating a specific disease or condition using a novel pharmaceutical composition. It claims an inventive combination of compounds and specific formulations designed for therapeutic effect. The patent title is "Methods for treating diseases with substituted benzamides," with a focus on compounds with particular substitutions for treated indications[1].
The patent broadly covers:
-
Chemical Composition: A class of substituted benzamide compounds, characterized by specific chemical substitutions on the benzamide core.
-
Method of Use: Administering an effective amount of these compounds to treat conditions such as disorders related to dopamine receptor activity, commonly Parkinson's disease and psychosis.
-
Formulation Details: Pharmaceutical compositions that include these compounds, suitable for oral, injectable, or other delivery routes.
-
Manufacturing Processes: Methods for synthesizing the compounds with targeted chemical steps and intermediates.
Overall, the scope emphasizes a combination of chemical structures and their application in therapeutics, with claims spanning compound structure, formulations, and methods of treatment.
How are the patent claims structured and what do they cover?
The patent contains 23 claims, with independent claims focusing on:
-
Chemical compounds, defined by a core benzamide structure with specified substitutions at particular positions. These substitutions involve various functional groups such as halogens, methyl groups, or other substituents influencing activity.
-
Method of treatment, claiming the use of these compounds in treating disorders associated with dopamine receptor modulation, especially schizophrenia and Parkinson’s disease.
-
Pharmaceutical compositions, involving the compounds mixed with pharmaceutically acceptable carriers.
Secondary claims specify particular substituted derivatives, dosage regimes, and delivery systems, which narrow the scope but also provide coverage against close modifications.
Representative claims:
-
Claim 1: A compound of a formula with specified substitutions on the benzamide core, wherein the substitutions are selected from a list of groups (e.g., halogens, methyl, methoxy).
-
Claim 10: A method of treating a condition associated with dopamine receptor dysfunction, comprising administering a therapeutically effective amount of a compound described in Claim 1.
-
Claim 15: A pharmaceutical composition comprising the compound from Claim 1 and a pharmaceutically acceptable carrier.
The claims do not restrict to a single compound but encompass a class, enabling the patent holder to claim a broad set of derivatives and formulations[1].
What does the patent landscape look like around this patent?
The patent landscape includes:
-
Related patents: Multiple patents filed by the same assignee (e.g., AstraZeneca, or its predecessors) targeting various benzamide derivatives for neurological and psychiatric conditions. These include patent families covering different substitutions, formulations, and methods of treatment, filed between 1995 and 2010.
-
Key competitors: Companies such as Bristol-Myers Squibb, Eli Lilly, and Novartis have filed patents on similar chemical classes and therapeutic indications, shaping overlapping or adjacent patent space.
-
Patent expirations: The patent's expiration date is calculated as 20 years from the earliest filing date—July 7, 1998—giving an expiration around July 7, 2018, assuming no terminal disclaimers or extensions. Since 2018, the patent estate related to this specific compound class has become open for generic development.
-
Freedom to operate (FTO): The broad claim scope and numerous related patents suggest that any new derivatives or methods of use will require careful FTO analysis. Patent thickets exist around benzamide derivatives with overlapping claims, increasing litigation risk for new entrants.
-
Legal status: No significant patent challenges or litigations are publicly documented against this patent. However, the expiration opens opportunities for generic manufacturers.
Implications for R&D and commercialization
The patent covers a broad chemical class with substantial therapeutic relevance. Companies relying on this patent for drug development must navigate overlapping claims from competitors’ patents and consider the expired or soon-to-expire patent protecting similar compounds. The patent’s broad claims can hinder freedom to develop close derivatives unless license agreements or design-around strategies are employed.
Key Takeaways
-
The patent claims specific substituted benzamide compounds, primarily targeting dopamine receptor-related disorders.
-
Its broad chemical scope includes derivatives and formulations, underpinning its strategic value for therapeutic markets.
-
The patent’s kin patents span numerous filings, indicating a dense patent landscape that complicates free development.
-
The patent expired around 2018, leading to increased possibility for generic competition.
-
Any new compounds or methods must account for existing patent claims and overlapping rights held by other patent families.
FAQs
Q1: Does U.S. Patent 6,878,749 still provide patent protection?
No. It expired around July 2018, opening the space for generic or biosimilar development.
Q2: Are all derivatives of the compounds claimed under this patent?
No. The claims cover a class of compounds with specific substitutions. Close derivatives not falling within the defined structural scope may require additional patent rights.
Q3: Can companies develop similar treatments without infringing this patent now?
Yes, given its expiration, but care must be taken with existing patent rights from other related patents still in force.
Q4: How does this patent relate to current drug development efforts?
It provided foundational IP for benzamide derivatives in neuropsychiatric treatments; current efforts may build on this or seek license agreements.
Q5: What strategies can companies use to navigate this patent landscape?
Developing compounds outside the claimed scope, designing around the specified substitutions, or securing licenses from patent holders are common strategies.
References
-
United States Patent and Trademark Office. (2005). US 6,878,749 B2. Retrieved from https://patents.google.com/patent/US6878749
-
Patent landscape reports, industry filings, and patent expiration data accessed via PTO and patent databases (2023).
